Three senior women hugging

OSTEOCOOL RF ABLATION for the treatment of painful bone tumours

See Clinical Evidence

latest news

Swift, significant, Sustained pain relief And improved quality of life

Image of Osteocool procedure

OUTCOMES IN 100 PATIENTS TREATED

The OsteoCool™ Post-Market Clinical Study (OPuS One) is one of the largest studies in radiofrequency (RF) ablation evaluating outcomes in patients with painful metastatic tumours and benign bone tumours. This multicenter study is collecting real world evidence on the effectiveness and safety of OsteoCool. OPuS One is a global, prospective, non-randomized, single-arm study. Data on the first 100 patients is now available.

Patient Feature

Cory's Story

Cory’s breast cancer metastasized to her spine and sacrum causing unrelenting lower back pain that brought her into the ER. Not wanting to remain on opioids for her pain, Cory asked her doctor about other options. Dr. Ramsin Benyamin at Millennium Pain Center in Normal, Ilinois (US) offered to treat Cory’s cancer pain with OsteoCool.

Product Overview

The OsteoCool RF ablation system is cooled radiofrequency ablation technology. It offers simultaneous, dual-probe capabilities for treating painful bone tumours, including benign and painful metastatic lesions. The system’s algorithms are designed to perform optimally in bone, allowing you to overcome challenges through a wide range of ablation scenarios, letting you treat patients confidently and consistently.

Contact Us About OsteoCool

Speak to your local Medtronic representative to learn more about OsteoCool Radiofrequency Ablation.

Request a call
Female healthcare professionals pointing forward

Indications, Safety, and Warnings

INDICATIONS

  • Intended for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body
  • Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy
  • Ablation of benign bone tumours such as osteoid osteoma

RISKS

  • As a consequence of electrosurgery, damage to surrounding tissue through iatrogenic injury could occur
  • Pulmonary embolism